These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9533981)

  • 81. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.
    Lalezari J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):195-7. PubMed ID: 9768631
    [No Abstract]   [Full Text] [Related]  

  • 82. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.
    Berginc K; Trontelj J; Kristl A
    Drug Metab Pharmacokinet; 2010; 25(3):307-13. PubMed ID: 20610890
    [TBL] [Abstract][Full Text] [Related]  

  • 83. HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?
    Maksimovic-Ivanic D; Fagone P; McCubrey J; Bendtzen K; Mijatovic S; Nicoletti F
    Int J Cancer; 2017 Apr; 140(8):1713-1726. PubMed ID: 27870005
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Drug interactions with antiretroviral agents].
    Furlan V; Taburet AM
    Therapie; 2001; 56(3):267-71. PubMed ID: 11475806
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro.
    Lazdins JK; Bold G; Capraro HG; Cozens R; Fässler A; Flesch G; Klimkait T; Lang M; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Walker MR; Woods-Cook K
    Schweiz Med Wochenschr; 1996 Oct; 126(43):1849-51. PubMed ID: 8916294
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Examining pharmacodynamic and pharmacokinetic properties of eleven analogues of saquinavir for HIV protease inhibition.
    Jayaswal A; Mishra H; Mishra A; Shah K
    Arch Virol; 2019 Apr; 164(4):949-960. PubMed ID: 30680529
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Gynaecomastia associated with saquinavir therapy.
    Donovan B; Bodsworth NJ; Mulhall BP; Allen D
    Int J STD AIDS; 1999 Jan; 10(1):49-50. PubMed ID: 10215131
    [No Abstract]   [Full Text] [Related]  

  • 88. Food consumption, cytochrome P450 3A4 (CYP3A4) presystemic inhibitors, and bioavailability of saquinavir.
    Amariles P
    Farm Hosp; 2007; 31(1):68-70. PubMed ID: 17439316
    [No Abstract]   [Full Text] [Related]  

  • 89. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.
    Aquaro S; Caliò R; Balzarini J; Bellocchi MC; Garaci E; Perno CF
    Antiviral Res; 2002 Aug; 55(2):209-25. PubMed ID: 12103427
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection.
    Hoetelmans RM; van Essenberg M; Meenhorst PL; Mulder JW; Beijnen JH
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):235-41. PubMed ID: 9367213
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Acute paranoid reaction to saquinavir.
    Finlayson JA; Laing RB
    Am J Health Syst Pharm; 1998 Oct; 55(19):2016-7. PubMed ID: 9784791
    [No Abstract]   [Full Text] [Related]  

  • 92. Saquinavir: From HIV to COVID-19 and Cancer Treatment.
    Pereira M; Vale N
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883499
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [New strategies for antiretroviral treatment in HIV infected patients].
    Garrait V; Molina JM
    Pathol Biol (Paris); 2001 Feb; 49(1):67-71. PubMed ID: 11265226
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.
    Gong Y; Haque S; Chowdhury P; Cory TJ; Kodidela S; Yallapu MM; Norwood JM; Kumar S
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):417-427. PubMed ID: 30951643
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Overview of protease inhibitors.
    Pakyz A; Israel D
    J Am Pharm Assoc (Wash); 1997; NS37(5):543-51. PubMed ID: 9479406
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy.
    Becker SL
    Expert Opin Investig Drugs; 2003 Mar; 12(3):401-12. PubMed ID: 12605563
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacokinetic interactions with rifampicin : clinical relevance.
    Niemi M; Backman JT; Fromm MF; Neuvonen PJ; Kivistö KT
    Clin Pharmacokinet; 2003; 42(9):819-50. PubMed ID: 12882588
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmacokinetic interaction between saquinavir and cyclosporine.
    Brinkman K; Huysmans F; Burger DM
    Ann Intern Med; 1998 Dec; 129(11):914-5. PubMed ID: 9867740
    [No Abstract]   [Full Text] [Related]  

  • 99. The effect of antiretrovirals on Plasmodium falciparum liver stages.
    Hobbs CV; De La Vega P; Penzak SR; Van Vliet J; Krzych U; Sinnis P; Borkowsky W; Duffy PE
    AIDS; 2013 Jun; 27(10):1674-7. PubMed ID: 23907270
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
    Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.